Wick, A., Desjardins, A., Suárez Rodríguez, C., Forsyth, P., Gueorguieva, I., Burkholder, T., & Rodon Ahnert, J. (2020). Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Citación estilo ChicagoWick, Antje, Annick Desjardins, Cristina Suárez Rodríguez, Peter Forsyth, Ivelina Gueorguieva, Tiana Burkholder, y Jordi Rodon Ahnert. Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-beta Receptor I, in Combination With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma. 2020.
Cita MLAWick, Antje, et al. Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-beta Receptor I, in Combination With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma. 2020.